Diazaindole-dicarbonyl-piperazinyl antiviral agents

1. A compound or a pharmaceutically acceptable salt thereof of Formula I,

wherein:

Q is

wherein R 3 is hydrogen, C 1 -C 3 alkoxy, —NR 26 R 9 or halogen;

T is —C(O)—;

R 1 is hydrogen;

R 5 is independently selected from the group consisting of C(O)NH 2 , C(O)NHCH 3 and C(O)NHheteroaryl; wherein said C(O)NHheteroaryl is optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from F;

R 2 and R 4 do not exist;

R 6 is (CH 2 ) n H, wherein n is 0;

-- represents a carbon-carbon bond;

—Y— is selected from the group consisting of

R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 are each independently H or methyl, with the proviso that a maximum of two of R 10 -R 17 is a methyl;

R 18 is a member selected from the group consisting of C(O)-phenyl, C(O)-heteroaryl, pyridinyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolyl, quinoxalinyl, napthyridinyl, pthalazinyl, azabenzofuryl and azaindolyl; wherein said member is optionally substituted with from one to two substituents selected from the group consisting of methyl, —amino, —NHMe, —NMe 2 , methoxy, hydroxymethyl and halogen;

D is selected from the group consisting of hydrogen, cyano, S(O) 2 R 24 , halogen, COOR 20 , C(O)NR 21 R 22 , phenyl and heteroaryl; wherein said phenyl or heteroaryl is independently optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from the group consisting of (C 1-6 )alkyl, (C 1-6 )alkenyl, hydroxy, (C 1-6 )alkoxy, halogen, —NR 24 R 25 , —S(O) 2 NR 24 R 25 , COOR 26 and —CONR 24 R 25 ; wherein said (C 1-6 )alkyl is optionally substituted with one to three same or different halogen or a hydroxyl;

A is selected from the group consisting of phenyl, pyridinyl, furanyl, thienyl, isoxazole and oxazole; wherein said phenyl, pyridinyl, furanyl, thienyl, isoxazole or oxazole is independently optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkenyl, (C 1-3 )alkoxy, halogen and —NR 2 ; wherein said (C 1-4 )alkyl is optionally substituted with one to three same or different halogens;

heteroaryl is selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, thienyl, benzothienyl, thiazolyl, oxazolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, tetrazolyl and triazolyl;

F is selected from the group consisting of (C 1-6 )alkyl, (C 1-6 )alkenyl, phenyl, pyridinyl, hydroxy, (C 1-6 )alkoxy, halogen, benzyl, —NR 23 C(O)—(C 1-6 )alkyl, —NR 24 R 25 , —S(O) 2 NR 24 R 25 , COOR 26 , —COR 27 , and —CONR 24 R 25 ; wherein said (C 1-6 )alkyl or phenyl are each optionally substituted with hydroxy, (C 1-6 )alkoxy, (C 1-6 )alkyl, CF 3 , dimethylamino or from one to three same or different halogen;

R 9 and R 26 are each independently selected from the group consisting of hydrogen and (C 1-6 )alkyl;

R 20 , R 23 , R 24 and R 25 are independently selected from the group consisting of hydrogen, (C 1-6 )alkyl, phenyl and heteroaryl; wherein said phenyl and heteroaryl are each independently optionally substituted with one to three same or different halogen or methyl;

R 21 and R 22 are each hydrogen; and

R 27 is piperazinyl, N-methyl piperazinyl, or 3-pyrazolyl.

2. A compound of claim 1 , wherein:

R 18 is —C(O)phenyl or —C(O) heteroaryl; wherein said heteroaryl is pyridinyl, furanyl or thienyl; wherein

heteroaryl is independently optionally substituted with a member selected from the group consisting of halogen, methyl, -amino, —NHMe, NMe 2 and hydroxymethyl.

3. A compound of claim 1 wherein:

—W— is

R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 are each independently H or methyl, with the proviso that not more than one is methyl; and

R 18 is selected from the group consisting of pyridinyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolyl, quinoxalinyl, napthyridinyl, pthalazinyl, azabenzofuryl and azaindolyl, each of which may be optionally substituted with from one to two substituents selected from the group consisting of methyl, -amino, —NHMe, —NMe 2 , methoxy, hydroxymethyl and halogen.

4. A compound of claim 1 wherein:

—W— is

and R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 are each independently H or methyl, with the proviso that one is methyl.

5. A compound or a pharmaceutically acceptable salt thereof,

wherein:

Q is

R 1 is hydrogen or methyl;

R 3 and R 5 are independently selected from the group consisting of hydrogen, halogen, cyano, nitro, COOR 8 , XR 9 and B;

R 2 and R 4 are independently O or do not exist, with the proviso that only one of R 2 and R 4 are O;

R 6 is (CH 2 ) n H, wherein n is 0-1;

-- represents a carbon-carbon bond or does not exist;

—Y— is selected from the group consisting of

R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 are each independently H or (C 1-6 )alkyl; wherein said (C 1-6 )alkyl may optionally be substituted with one to three same or different halogen, OH or CN;

R 18 is a member selected from the group consisting of C(O)-phenyl, C(O)-heteroaryl, pyridinyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolyl, quinoxalinyl, napthyridinyl, pthalazinyl, azabenzofuryl and azaindolyl;

wherein said member is optionally substituted with from one to two substituents selected from the group consisting of methyl, -amino, —NHMe, —NMe 2 , methoxy, hydroxymethyl and halogen;

D is selected from the group consisting of hydrogen, cyano, S(O) 2 R 24 , halogen, COOR 20 C(O) NR 21 R 22 , phenyl and heteroaryl; wherein said phenyl or heteroaryl is independently optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from F;

A is selected from the group consisting of phenyl, pyridinyl, furanyl, thienyl, isoxazole and oxazole; wherein said phenyl, pyridinyl, furanyl, thienyl, isoxazole or oxazole is independently optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from F;

B is selected from the group consisting of (C 1-6 )alkyl, C(O)NR 21 R 22 , phenyl and heteroaryl; wherein said (C 1-6 )alkyl, phenyl and heteroaryl are independently optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from F;

heteroaryl is selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, tetrazolyl and triazolyl;

F is selected from the group consisting of (C 1-6 )alkyl, (C 1-6 )alkenyl, phenyl, pyridinyl, hydroxy, (C 1-6 )alkoxy, halogen, benzyl, —NR 23 C(O)—(C 1-6 )alkyl, —NR 24 R 25 ,

—S(O) 2 NR 24 R 25 , COOR 26 , —COR 27 , and —CONR 24 R 25 ; wherein said (C 1-6 )alkyl or phenyl are each optionally substituted with hydroxy, (C 1-6 )alkoxy, dimethylamino or from one to three same or different halogen;

R 8 , R 9 and R 26 are each independently selected from the group consisting of hydrogen and (C 1-6 )alkyl;

X is selected from the group consisting of NR 26 , O and S;

R 20 , R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from the group consisting of hydrogen, (C 1-6 )alkyl, phenyl and heteroaryl; wherein said phenyl and heteroaryl are each independently optionally substituted with one to three same or different halogen or methyl; and

R 27 is piperazinyl, N-methylpiperazinyl or 3-pyrazolyl.

6. A compound or a pharmaceutically acceptable salt thereof of Formula I,

wherein Q is

T is —C(O)—;

R 5 is selected from the group consisting of hydrogen, halogen, cyano, XR 9 , heteroaryl, —(CH 2 CH 2 ) 2 NC(O)pyrazolyl, and —C(O) CH 3 , wherein said heteroaryl is optionally substituted with one substituent selected from F;

heteroaryl is selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, isoxazolyl, isoxazolyl, pyrazolyl, and triazolyl;

—Y— is selected from the group consisting of

R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 are each hydrogen;

A is phenyl or pyridinyl;

R 18 is C(O)-phenyl, isoquinolyl or quinazolyl;

D is cyano or oxadiazolyl;

F is selected from the group consisting of (C 1-6 )alkyl, phenyl, pyridinyl, (C 1 -2 )alkoxy, —COOR 26 —COR 27 and —CONR 24 R 25 ; wherein said phenyl is optionally substituted with one group selected from methyl, methoxy, fluoro, or trifluoromethyl;

X is selected from the group consisting of O;

R 9 is (C 1-2 )alkyl;

R 26 is hydrogen, methyl, or ethyl;

R 24 and R 25 are independently selected from the group consisting of hydrogen and methyl; and

R 27 is piperazinyl, N-methyl piperazinyl, or 3-pyrazolyl.

7. A compound of claim 6 wherein:

R 5 is heteroaryl optionally substituted with one substituent selected from F;

—Y—is

R 18 is C(O)-phenyl, isoquinolyl or quinazolyl; and

F is (C 1-6 )alkyl.

8. A compound of claim 7 wherein R 18 is C(O)-phenyl.

9. A compound of claim 7 wherein R 18 is isoquinolyl or quinazolyl.

10. A compound of claim 6 wherein:

R 5 is heteroaryl optionally substituted with one substituent selected from F;

heteroaryl is selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, isoxazolyl, isoxazolyl, pyrazolyl and triazolyl; and

—Y—is

11. A compound of claim 6 wherein:

Q is

R 5 is heteroaryl optionally substituted with one substituent selected from F; and

heteroaryl is selected from the group consisting of pyrazolyl and triazolyl.

12. A compound of claim 11 wherein:

F is selected from the group consisting of methyl and —CONR 24 R 25 ; and

R 24 and R 25 are independently selected from the group consisting of hydrogen and methyl.

13. A compound of claim 12 wherein:

F is methyl.

14. A pharmaceutical composition which comprises an antiviral effective amount of a compound or a pharmaceutically acceptable salt thereof of Formula I, as claimed in claim 1 , and one or more pharmaceutically acceptable carriers, excipients or diluents.

15. A method of ameliorating HIV comprising administering to a mammal an antiviral effective amount of a compound of Formula I, including pharmaceutically accceptable salts thereof, as claimed in claim 1 , and one or more pharmaceutically acceptable carriers, excipients or diluents.

16. The method of claim 15 comprising administering to said mammal an antiviral effective amount of a compound of Formula I, including pharmaceutically accceptable salts thereof, in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and an HIV entry inhibitor.